Principal
Investigator: Richard Rosen, MD
Enrollment
Status: Open Enrollment
Objective:
To assess the efficacy of intravitreal (ITV) administered VEGF Trap compared to Lucentis (ranibizumab) in a non-inferiority paradigm in preventing moderate vision loss in subjects with all subtypes of neovascular AMD.
Eligibility:
Contact
Information: Anita Ou, CRC (212)-979-4671; Katy Tai, CR Manager (212) 979-4251
|